Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Net Margin: 2022-2025

Historic Net Margin for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -60.53%.

  • Phathom Pharmaceuticals' Net Margin rose 46276.00% to -60.53% in Q3 2025 from the same period last year, while for Sep 2025 it was -186.44%, marking a year-over-year increase of 110543.00%. This contributed to the annual value of -605.08% for FY2024, which is 2892630.00% up from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Net Margin stood at -60.53%, which was up 68.39% from -191.52% recorded in Q2 2025.
  • Over the past 5 years, Phathom Pharmaceuticals' Net Margin peaked at 1,473.65% during Q1 2022, and registered a low of -11,665.10% during Q4 2023.
  • Its 3-year average for Net Margin is -1,576.30%, with a median of -251.15% in 2024.
  • As far as peak fluctuations go, Phathom Pharmaceuticals' Net Margin slumped by 1,223,745bps in 2023, and later spiked by 1,141,396bps in 2024.
  • Over the past 4 years, Phathom Pharmaceuticals' Net Margin (Quarterly) stood at 572.35% in 2022, then crashed by 1,223,745bps to -11,665.10% in 2023, then skyrocketed by 1,141,396bps to -251.15% in 2024, then surged by 46,276bps to -60.53% in 2025.
  • Its last three reported values are -60.53% in Q3 2025, -191.52% for Q2 2025, and -330.64% during Q1 2025.